The goal of this clinical trial is to investigate if a single dose of oral SGLT2i, (50 mg Jardiance) will change oxygen tension in the kidney transplant.

The main questions it aims to answer are:

• Does a single dose of oral SGLT2i (50 mg Jardiance) change oxygen tension in the kidney transplant cortex and medulla, estimated by magnetic resonance imaging?
• Does a single dose of oral SGLT2i (50 mg Jardiance) change kidney transplant cortical and medullary perfusion?
• Does a single dose of oral SGLT2i (50 mg Jardiance) change kidney transplant artery blood flow?
• Does a single dose of oral SGLT2i (50 mg Jardiance) change blood glucoses, blood pressure and heart rate?

Researchers will compare a single dose of oral SGLT2i (50 mg Jardiance) to a placebo (a look-alike substance that contains no drug) to see if a single dose of oral SGLT2i (50 mg Jardiance) changes oxygen tension in the kidney transplant.

Kidney transplant recipients with out diabetes will:

• Meet for two intervention days.
• A single dose of oral SGLT2i (50 mg Jardiance) or placebo will be given in random order, separated by at least 2 week washout period, the experiment will be repeated with the opposite treatment.
• Kidney cortex oxygenation, and blood flow in different compartments of the kidney transplant, is estimated by blood-oxygen-dependent level magnetic resonance imaging (BOLD-MRI). Patients are evaluated by routine clinical examination and routine biochemical measures for kidney transplant patients.

Background:

Kidney transplantation is the best treatment of end-stage renal disease (ESRD), although median allograft survival is only 15 years. In non-transplant diabetic and non-diabetic patient's sodium-glucose co-transporter type 2 inhibitors (SGLT2i) protect kidney function, possibly by reducing the proximal tubule transport workload with subsequent improvement of renal oxygenation and relieve hypoxia.

Hypothesis:

SGLT2i in kidney transplant recipients (KTR) will improve kidney allograft cortex oxygenation.

Research Objective:

We aim to test the acute effect of SGLT2i on kidney allograft oxygen tension.

Design:

A randomized, double-blind, placebo-controlled, crossover intervention study. Designed according to the CONSORT statement

Methods:

A single dose of oral SGLT2i (50 mg Jardiance) and placebo in random order, separated by at least 2 week washout period, the experiment will be repeated with the opposite treatment.

Kidney cortex oxygenation and blood flow in different compartments of the kidney allograft will be estimated by blood-oxygen-dependent level magnetic resonance imaging (BOLD-MRI). Patients will be evaluated by routine clinical examination and routine biochemical measures for transplant patients.

Primary endpoint:

- Kidney allograft cortical and medullary oxygen tension, estimated by BOLD-MRI based renal T2* relaxation rate.

Secondary endpoint:

• Renal cortical and medullary perfusion ml/100 g/min
• Renal artery blood flow ml/min
• Blood glucose mmol/L
• Systolic blood pressure (SysBP) and diastolic blood pressure (DiaBP) mmHg
• Heart rate (HR), beats min-1

Study population:

8 Non-diabetic kidney transplant recipients > 6 months post-transplant and stable eGFR >20 ml/min will be recruited from Odense University Hospital (OUH) kidney transplant outpatient clinic.

Inclusion Criteria:

• Male or female patients, age ≥ 18 years.

• Non-diabetic kidney transplant recipients

• > 6 months post-transplant

• Stable eGFR> 20 ml/min (defined as eGFR 20 ml/min ± 5 ml/min variation in the last 3 months)

• Immunosuppressive: Tacrolimus (Adport) and Mycophenolatmofetil (Myfenax/Cellcept/Mycophenolatmofetil)

• Capable of lying in a MR-scanner

• Capable of providing a signed informed consent and comply with study requirements.

  • Negativ pregnancy test

Exclusion Criteria:

• Diabetic kidney disease type 1 or 2 (World Health Organization (WHO) criteria)

  • Hemoglobin A1c ≥ 48 mmol/mol
  • Fasting venous plasma glucose ≥ 7,0 mmol/l or
  • 2-hours venous plasma glucose ≥ 11,1 mmol/l after oral glucose tolerance test (OGTT).

• Renal allograft failure (eGFR< 20 ml/min)

• Alanine aminotransferase (ALAT) > 3 x upper normal limit

• Bilirubin > 2 x upper normal limit

• Prednisone treatment

• Pregnancy

• Breastfeeding

• Exclusion criteria for MRI o Claustrophobia/physical not able to lie in MR-s

Data Sharing Statement:

Data Available:

Individual participant data (IPD) that underlie the results reported in the published article will be shared after de-identification. This includes text, tables, figures, and appendices.

Supporting Documents:

The study protocol and statistical analysis plan will also be made available.

Time Frame:

Data will be shared immediately following publication. There is no specified end date for availability.

Criteria for Access:

Data will be shared with researchers who submit a methodologically sound proposal aimed at achieving the goals outlined in their approved research proposal.

Access Mechanism:

Interested researchers should direct their proposals to: lotte.borg.lange@rsyd.dk.

To gain access, requestors will be required to sign a data access agreement.

Data Storage:

The data will be stored for 25 years on a secure third-party platform (OPEN).

The data will be available after the last patients last visit, which is estimated for summer 2025

Data Storage:

The data will be stored for 25 years on a secure third-party platform (OPEN).

Criteria for Access:

Data will be shared with researchers who submit a methodologically sound proposal aimed at achieving the goals outlined in their approved research proposal.

Access Mechanism:

Interested researchers should direct their proposals to: lotte.borg.lange@rsyd.dk.

To gain access, requestors will be required to sign a data access agreement.